Healthcare
Live Price
Offline$0.024
+0.00% today
1Y Change
-14.29%
Window
Jun 20, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 20, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SQZ Biotechnologies Company (SQZB) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and down 14.3% across the available one-year price window (Jun 20, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -22.4%, EPS growth of -10.8%, a dividend yield of 0.0%. What stands out right now is revenue -22.4%, EPS -10.8%, free cash flow -1.6% with operating margin -383.7% and ROIC -81.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SQZB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SQZB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SQZB Max Drawdown
-23.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SQZB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$12.7M
-37.0% YoY
FY Net Income
-$20.2M
+37.2% YoY
Free Cash Flow
$19.8M
+155.5% YoY
Revenue Growth
-22.4%
EPS Growth
-10.8%
Gross Margin
46.6%
Net Margin
-377.9%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 21M | 27M | 21M | 20M | 13M |
| Gross Profit | 10M | 16M | 21M | 20M | 13M |
| Operating Income | -81M | -69M | -51M | -34M | -20M |
| EBITDA | -64M | -58M | -40M | -30M | -18M |
| Net Income | -79M | -69M | -51M | -32M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 64M | 144M | 170M | 39M | 60M |
| Total Assets | 107M | 226M | 231M | 152M | 116M |
| Total Liabilities | 50M | 102M | 104M | 94M | 53M |
| Shareholder Equity | 57M | 124M | 127M | 59M | 63M |
| Total Debt | 34M | 70M | 47M | 42M | 0 |
| Net Debt | -29M | -74M | -123M | 3M | -60M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
21M
+163.0% YoY
Capital Expenditures
1M
+39.8% YoY
Free Cash Flow
20M
+155.5% YoY
Key ratios
Gross Margin
46.6%
Operating Margin
-383.7%
Net Margin
-377.9%
ROE
-87.7%
Debt / Equity
0.60x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.